Status Migrainosus - Differentiating Between Responders and Non-responders in the Setup of Real-life Clinical Practice

Trial Profile

Status Migrainosus - Differentiating Between Responders and Non-responders in the Setup of Real-life Clinical Practice

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Aug 2018

At a glance

  • Drugs Bupivacaine (Primary) ; Dexamethasone (Primary) ; Ketorolac (Primary) ; Ketorolac (Primary) ; Naratriptan (Primary)
  • Indications Migraine without aura
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 31 Jul 2018 Planned End Date changed from 30 Jun 2018 to 30 Jun 2020.
    • 31 Jul 2018 Planned primary completion date changed from 31 Dec 2017 to 31 Dec 2019.
    • 03 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top